Table 1.
Baseline patient characteristics (n=114)
| Median age (range) | 52 (34–74) |
| ECOG performance status，n (%) | |
| 0 | 46 (40.4) |
| 1 | 68 (59.6) |
| Hormonal receptor status，n (%) | |
| Both ER and PgR negative | 35 (30.7) |
| ER and (or) PgR positive | 78 (68.4) |
| ER and PgR status unknown | 1 (0.9) |
| HER2 status，n (%) | |
| HER2 positive | 35 (30.7) |
| HER2 negative | 78 (68.4) |
| HER2 unkown | 1 (0.9) |
| Metastatic sites，n (%) | |
| Brain | 18 (15.8) |
| Lung | 48 (42.1) |
| Liver | 52 (45.6) |
| Bone | 62 (54.4) |
| Lymph nodes | 73 (64.0) |
| Chest wall or skin | 11 (9.6) |
| Visceral disease，n (%) | 89 (78.1) |
| Chemotherapy line，n(%) | |
| 1 | 41 (36.0) |
| 2 | 29 (25.4) |
| ≥3 | 44 (38.6) |
| Drug combination, n (%) | |
| Gemcitabine | 17 (14.9) |
| Taxol | 41 (36.0) |
| Docetaxel | 11 (9.6) |
| Vinorelbine | 15 (13.2) |
| Pemetrexed | 23 (20.1) |
| Albumin-bound paclitaxel | 6 (5.3) |
| Liposomal doxorubicin | 1 (0.9) |
Abbreviations: PR, partial response; PgR, progesterone receptor.